Market Cap | 387.51K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -907.32k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
Sales | 4.04M | PEG | - | EPS past 5Y | - | 200D Avg Chg | - |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | - |
Recommedations | - | Quick Ratio | 0.34 | Shares Outstanding | 15.50M | 52W Low Chg | - |
Insider Own | - | ROA | -10.27% | Shares Float | - | Beta | -0.14 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00010 |
Gross Margin | 39.92% | Profit Margin | -22.45% | Avg. Volume | 1,641 | Target Price | - |
Oper. Margin | -4.99% | Earnings Date | - | Volume | 5,620 | Change | 0.00% |
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines. In addition, the company provides veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. It sells its products directly, as well as through distributors to various laboratories, hospitals, and blood banks. The company was founded in 1985 and is based in Columbia, Maryland.